Among all patients, 1342 patients were diagnostic as EGFR- or ALK-mutated advanced NSCLC (IIIB/IV/recurrent stage) and were treated with standardized EGFR-TKIs or ALK-TKIs targeted therapy. Here, EGFR is linked to non-small cell lung carcinoma.